Alivus Life Sciences Sets Sept 1 as Record Date for ₹5 Dividend, AGM on Sept 8
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The record date for a ₹5 per equity share final dividend for FY26 is set for September 1, 2026. Dividend payments are expected on or after September 11, 2026, subject to AGM approval.
The declaration of a dividend and setting a record date directly impacts shareholders' entitlements, making it a medium-impact announcement.
The announcement of a final dividend and a record date for its payment is generally positive for shareholders.
Alivus Life Sciences Limited (formerly Glenmark Life Sciences Limited) has announced that its Fifteenth Annual General Meeting (AGM) will be held on Tuesday, September 8, 2026, at 3:00 PM IST via Video Conferencing or Other Audio-Visual Means. The Board of Directors had previously recommended a final dividend of ₹5.00 per equity share of ₹2 each for the financial year ended March 31, 2026. Pursuant to Regulation 42 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the company has fixed Tuesday, September 1, 2026, as the Record Date to determine shareholder entitlement for this dividend. If approved at the AGM, the dividend payment, after tax deduction, is scheduled to be made on or after Friday, September 11, 2026. This information will also be posted on the company's website, www.alivus.com.
What to do with a filing like this
Alivus Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under agm. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Alivus Life Sciences Limited. Read the original for the full detail.